IL33 and asthma: More recently, ES-62 was found to inhibit IL-33/ST2/MyD88 signaling and modulate the pro-inflammatory responses resulting from crosstalk between ST2, FcεRI, and TLR4, which may contribute to reported protective effects of ES-62 in chronic models of asthma (81).